VYGR
Voyager Therapeutics, Inc. Common StockRecent alerts on VYGR
All signals →
SEC filing
VYGR Receives FDA Clearance for VY1706 IND, Plans Phase 1 Trial for Alzheimer's Gene Therapy
1d ago
News
Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge
41d ago
SEC filing
VYGR Resigns CFO Jorgensen, Appoints Swartz CFO, Quinlan PACCO
41d ago
SEC filing
VYGR Reports $15.3M Q4 Revenue, $134.7M R&D Spend, $202M Cash Runway to 2028, VY1706 GLP Study Q1 2026, VY7523 MAD Completion, NeuroShuttle Proof-of-Concept
84d ago
Insider trade
Sale by Nathan D. Jorgensen (Chief Financial Officer)
95d ago
Insider trade
Sale by Todd Alfred Carter (Chief Scientific Officer)
95d ago
Insider trade
Sale by Alfred Sandrock (President and CEO)
95d ago
Insider trade
Sale by Robin Swartz (COO & CBO)
95d ago
Get push alerts for VYGR
Add it to your watchlist in the app and receive every signal the moment it fires.
Download for iOS